Loading clinical trials...
Loading clinical trials...
The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Biota Pharma Europe Limited
NCT06998251 · Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection, and more
NCT07128121 · Respiratory Syncytial Virus (RSV) Infection
NCT07164430 · Respiratory Syncytial Virus (RSV) Infection, Respiratory Syncytial Virus Hospitalizations, and more
Biota Investigational Site
London
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions